The verdict
Our read at a glance.
Whether displacing testosterone from its carrier protein produces a real benefit or just a different number on a blood test.
- The signal
- Mesterolone has a genuine clinical history in male hypogonadism and male infertility contexts and retains approvals in several countries, though not the United States, and the older literature covers those uses. Its distinctive pharmacology - strong binding to sex hormone binding globulin - is well characterised. What has not been studied is the use it now has: nobody has tested whether adding it alongside supraphysiologic androgens improves libido, mood or body composition, so that claim rests entirely on user report and on the mechanistic argument.
- The unknown
- Whether raising free testosterone by displacement produces any clinical benefit when total testosterone is already far above physiological range, which is the situation it is usually used in.
- Our read
- A coherent mechanism doing work in the absence of a measurement. Displacing testosterone from SHBG really does raise the free fraction; whether that matters when total testosterone is already several times normal is a question nobody has asked, and the libido claim is the kind most vulnerable to expectation.
The mechanism
How it works.
Most circulating testosterone is bound to sex hormone binding globulin and albumin, and only the small unbound fraction is available to act on tissue. Mesterolone is 1-methyl-dihydrotestosterone, and its notable property is very high affinity for SHBG - higher than testosterone's. Occupying those binding sites displaces testosterone from the carrier, raising the free fraction without changing the total, which is the mechanistic basis for the claim that it amplifies whatever androgen is already present. As a dihydrotestosterone derivative it cannot be aromatised, so it contributes no oestrogen, and it is a relatively weak anabolic agent at the androgen receptor while being strongly androgenic - which is why it is used as an adjunct rather than as a mass builder. The same 5-alpha-reduced structure is why its androgenic side effects on hair and skin are disproportionate to its size.
Safety & regulatory boundary
The consequential part.
No FDA-approved product in the United States; a Schedule III controlled substance there. It is a dihydrotestosterone derivative, so it does not aromatise and offers no oestrogen, and it is strongly androgenic relative to its anabolic effect - the predictable liabilities are scalp hair loss, acne, prostate effects and, in women, virilisation. It suppresses the gonadal axis, less than a full anabolic dose but not negligibly. Prohibited in sport.
What's next
What we're watching.
Nothing in development. Any controlled study of SHBG displacement in a supraphysiologic setting would be the first real evidence.
Context
Why this is discussed.
It is the standard answer to low libido and flat mood on cycle, and it is described as raising free testosterone without adding much suppression of its own.
The evidence base
12 cited references.
Indexed literature (PubMed)12
Asfour HA et al. · Sci Rep · 2021
Choudhary MI et al. · Chem Biodivers · 2005
Szöllösi J et al. · Int Urol Nephrol · 1978
Int J Androl · Int J Androl · 1989
Lu J et al. · J Mass Spectrom · 2015
Allouh MZ et al. · Anat Rec (Hoboken) · 2012
Baran L et al. · Pol J Pharmacol Pharm · 1981
Fontana K et al. · J Electron Microsc (Tokyo) · 2010
Drug Ther Bull · Drug Ther Bull · 1972
Dołowy M et al. · Biomed Res Int · 2015
Kiousi P et al. · J Mass Spectrom · 2015
Pérez Palacios D et al. · Gastroenterol Hepatol · 2019
Keep reading